IP receptor (prostacyclin pathway) drugs for Pulmonary Hypertension Associated with Interstitial Lung Disease
4 tracked IP receptor (prostacyclin pathway) drugs in the Pulmonary Hypertension Associated with Interstitial Lung Disease race. The class explanation lives on the IP receptor (prostacyclin pathway) page; the full indication pipeline across every mechanism is on the Pulmonary Hypertension Associated with Interstitial Lung Disease page.
3 approved / phase 41 Phase 3
Head-to-head evidence: Treprostinil (L606) vs Treprostinil (Tyvaso) · Treprostinil (Tyvaso) vs Treprostinil (Tyvaso DPI) · Treprostinil (Tyvaso) vs Treprostinil (Yutrepia, Liquidia)